Alzheimer's disease (AD) is a neurodegenerative disorder molecularly characterized by the
formation of amyloid β (Aβ) plaques and type 2 microtubule-associated protein (Tau) …

Genome-wide association studies and functional genomics studies have linked specific cell
types, genes, and pathways to Alzheimer's disease (AD) risk. In particular, AD risk alleles …

Targeting neuroinflammation via CD33 inhibition and/or TREM2 activation may have
important implications for neurodegeneration in Alzheimer's disease and may be an addition …

Alzheimer's disease (AD) is a debilitating, chronic neurodegenerative disease. Genetic
studies involving genome-wide association studies (GWAS) and meta-analysis have …

The current clinical trial landscape targeting Alzheimer's disease (AD) is reviewed in the
context of studies completed from 2019 to 2021. This review focuses on available data for …

Alzheimer's disease (AD) is the most common cause of dementia, affecting millions of
people worldwide, and no cure is currently available. The major pathological hallmarks of …

Microglia are brain macrophages that mediate neuroinflammation and contribute to and
protect against neurodegeneration. The terminal sugar residue of all glycoproteins and …

Alzheimer's disease (AD) is the most common form of neurodegenerative disease and is
considered the main cause of dementia worldwide. Genome-wide association studies …

Alzheimer's disease (AD) is an aging-related form of dementia associated with the
accumulation of pathological aggregates of amyloid beta and neurofibrillary tangles in the …

Glycosylation has been found to be altered in the brains of individuals with Alzheimer's
disease (AD). However, it is unknown which specific glycosylation-related pathways are …